Journal
JOURNAL OF VIROLOGY
Volume 94, Issue 9, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01845-19
Keywords
CTL; HDACi; HIV; RNA splicing; epigenetics; latency; reservoir
Categories
Funding
- NIH [AI131798, AI147845]
- Martin Delaney BELIEVE Collaboratory (NIH) [1UM1AI26617]
- NIAID
- NCI
- NICHD
- NHLBI
- NIDA
- NIMH
- NIA
- FIC
- OAR
Ask authors/readers for more resources
Clinical trials investigating histone deacetylase inhibitors (HDACi) to reverse HIV-1 latency aim to expose reservoirs in antiretroviral (ARV)-treated individuals to clearance by immune effectors, yet have not driven measurable reductions in the frequencies of infected cells. We therefore investigated the effects of the class I-selective HDACi nanatinostat and romidepsin on various blocks to latency reversal and elimination, including viral splicing, antigen presentation, and CD8(+) T cell function. In ex vivo CD4(+) T cells from ARV-suppressed individuals, both HDACi significantly induced viral transcription, but not splicing nor supernatant HIV-1 RNA. In an HIV-1 latency model using autologous CD8(+) T cell clones as biosensors of antigen presentation, neither HDACi-treated CD4(+) T cell condition induced clone degranulation. Both HDACi also impaired the function of primary CD8(+) T cells in viral inhibition assays, with nanatinostat causing less impairment. These findings suggest that spliced or cell-free HIV-1 RNAs are more indicative of antigen expression than unspliced HIV-RNAs and may help to explain the limited abilities of HDACi to generate CD8(+) T cell targets in vivo. IMPORTANCE Antiretroviral (ARV) drug regimens suppress HIV-1 replication but are unable to cure infection. This leaves people living with HIV-1 burdened by a lifelong commitment to expensive daily medication. Furthermore, it has become clear that ARV therapy does not fully restore health, leaving individuals at elevated risk for cardiovascular disease, certain types of cancers, and neurocognitive disorders, as well as leaving them exposed to stigma. Efforts are therefore under way to develop therapies capable of curing infection. A key focus of these efforts has been on a class of drugs called histone deacetylase inhibitors (HDACi), which have the potential of exposing hidden reservoirs of HIV-1 to elimination by the immune system. Unfortunately, clinical trial results with HDACi have thus far been disappointing. In the current study, we integrate a number of experimental approaches to build a model that provides insights into the limited activity of HDACi in clinical trials and offers direction for future approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available